In order to provide clinical evidences to our hypothesis that PP2A determines doxorubicin resistance, we analyzed the PP2A inhibition status (CPscore) in an independent set of 35 patients with locally advanced breast cancer who received neoadjuvant anthracycline-based chemotherapy. The gene discussed is PTPA; the disease is breast carcinoma.